Company Encyclopedia
View More
name
Porton
300363.SZ
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. It also offers crystallization, bio catalysis, metal catalysis, flow chemistry, prep-chromatography, and milling.
3.159 T
300363.SZMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking99/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-0.03%D
    • Profit Margin-0.04%D
    • Gross Margin32.24%C
  • Growth ScoreB
    • Revenue YoY24.51%A
    • Net Profit YoY99.64%A
    • Total Assets YoY-3.82%D
    • Net Assets YoY-1.08%D
  • Cash ScoreC
    • Cash Flow Margin-243636.94%E
    • OCF YoY24.51%A
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreB
    • Gearing Ratio35.99%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Porton released its performance for the first three quarters, with a net profit attributable to the parent company of 79.9154 million yuan, an increase of 138.71%

    Porton released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 2.544 billion yuan, a year-on-year increase of 19.72%. The net profit attributable to shareholders of the listed company was 79.9154 million yuan, a year-on-year increase of 138.71%. The net profit after deducting non-recurring gains and losses was 53.6788 million yuan, a year-on-year increase of 125.14%. The basic earnings per share were 0.15 yuan

    Zhitong·
    SZ
    300363
    0.00%
    Zhitong·
    SZ
    300363
    0.00%

    Porton issued a profit warning, expecting a net profit attributable to shareholders of 73.2 million to 88.2 million yuan in the first three quarters, turning losses into profits

    According to the Zhitong Finance APP, Porton disclosed its performance forecast for the first three quarters of 2025. The company expects a net profit attributable to shareholders of the listed company to be between 73.2 million yuan and 88.2 million yuan, turning a profit; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be between 50 million yuan and 65 million yuan

    Zhitong·
    SZ
    300363
    0.00%
    Zhitong·
    SZ
    300363
    0.00%

    Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

    Innovative drug concept stocks fluctuated and rose sharply, DEZHAN HEALTHCARE hit the limit up, Porton, JOINN, NHWA, Konruns, and SHANGHAI YIZHONG followed suit

    Zhitong·
    SH
    603127
    +0.47%
    HK
    06127
    -0.37%
    SZ
    002262
    +0.28%
    Zhitong·
    SH
    603127
    +0.47%
    HK
    06127
    -0.37%
    SZ
    002262
    +0.28%

    Zhejiang Merchants Securities: The growth trend of the CXO sector in 25H1 continues to improve, and the construction projects remain at a high level

    Zhejiang Merchants Securities released a research report indicating that from Q1 2024 to Q2 2025, the revenue of leading CXO companies will increase quarter-on-quarter and year-on-year. It is expected that the year-on-year revenue growth will return to positive in Q1 2025, reaching 8.2%, and further increase to 11.6% in Q2 2025. The high level of ongoing construction projects shows that CXO companies are optimistic about capacity expansion. Overall, the performance and fundamental turning point of the CXO industry are the main driving factors

    Zhitong·
    SZ
    300347
    -0.28%
    HK
    03347
    -0.31%
    SZ
    300725
    +0.32%
    Zhitong·
    SZ
    300347
    -0.28%
    HK
    03347
    -0.31%
    SZ
    300725
    +0.32%

    Porton Biotech and Tianyu Life have reached a strategic cooperation to jointly promote the research and commercialization of NK cell therapy

    According to Porton, on September 2nd, Suzhou Porton Biopharma Co., Ltd. and Zhejiang Tianyu Life Science Technology Co., Ltd. announced a strategic cooperation to jointly promote the research and industrialization of NK cell therapy technology. According to the agreement, Porton Biopharma will provide process development, GMP production, and registration application services for Tianyu Life's NK cell therapy project, assisting Tianyu Life in successfully obtaining clinical approval for its NK cell therapy drugs

    Zhitong·
    SZ
    300363
    0.00%
    Zhitong·
    SZ
    300363
    0.00%
    © 2025 Longbridge｜Disclaimer